Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Céline Blaye, MD, University of Bordeaux, Bordeaux, France, discusses the transforming landscape of immunotherapy for the treatment of breast cancer, including the hormone-mediated microenvironment of luminal breast cancer. This type of environment impairs immunotherapeutic strategies, providing the rationale for investigating myeloid cells to evaluate whether this can be reversed to render immunotherapeutic strategies efficacious in this disease setting. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.